Pharmacists’ Approach to Optimise Safe Medication Use in Paediatric Patients
Abstract
:1. Introduction
2. Paediatric Dosing Challenges
3. Nine Rights Principles
3.1. Right Medicine and Right Formulation
- Adco-Magnesium®, Adco-Metoclopramide®, and Adco-Furosemide®;
- Sandoz Co-Amoxyclav SF® 250 mg/5 mL and Sandoz Co-Amoxyclav S® 125 mg/5 mL;
- Ampicillin Fresenius® 500 mg and Ampicillin Fresenius® 250 mg;
- Adco-Ipratropium® and Adco-Fenoterol®.
3.2. Right Patient
3.2.1. Age and Weight
3.2.2. Allergies
3.2.3. Ability to Swallow
3.2.4. Fluid Restriction
3.3. Right Indication
3.4. Right Dose
3.4.1. Reconstitution versus Dilution
3.4.2. Calculating the Dose
- assist in easy administration for carers/healthcare workers;
- reduce administration errors; and
- prevent over- and underdosing of paediatric patients.
Available product: Augmentin
125 mg (amoxicillin)/31.25 mg (clavulanic acid)/5 mL suspension = (375 mg/125 mg) × 5 mL = 15 mL
Available product: Augmentin
250 mg (amoxicillin)/62.5 mg (clavulanic acid)/5 mL suspension = (375 mg/250 mg) × 5 mL = 7.5 mL
Available product: paracetamol (120 mg/5 mL) = (360 mg/120 mg) × 5 mL = 15 mL
Rx ferrous gluconate = 60 mg per od
Available product: ferrous gluconate (8 mg/1 mL) = (60 mg/8 mg) × 1 mL = 7.5 mL
Available product: Augmentin
125 mg (amoxicillin)/31.25 mg (clavulanic acid)/5 mL suspension = (375 mg/125 mg) × 5 mL = 15 mL
Dosage based on amoxicillin component.
Rx cotrimoxazole = 20 mg per 6 h
Available product: sulfamethoxazole (200 mg)/trimethoprim (40 mg)/5 mL = (20 mg/40 mg) × 5 mL = 2.5 mL
Dosage based on trimethoprim component.
Available product: spironolactone (25 mg) (can be halved since it is scored)
Using half, a tablet dissolved in 5 mL = (3.125 mg/12.5 mg) × 5 mL = 1.25 mL
Using half, a tablet dissolved in 10 mL = (3.125 mg/12.5 mg) × 10 mL = 2.5 mL
3.4.3. Kidney Function
3.4.4. Hepatic Function
3.4.5. TDM
3.5. Right Measuring Equipment
3.6. Right Route of Administration
3.7. Right Time
3.8. Right Duration
4. Medication Storage
5. Pharmacists’ Role in Paediatric Medicine
- An undesirable event or risk of an event,
- Medication therapy of the patient, and
- A relationship between the undesirable event and medication therapy [39].
Education and Counselling
- explaining the instructions to administer the medicines,
- providing a practical demonstration of how to administer the medicines, and
- marking the appropriate dose on the measuring equipment.
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Wu, A. Minimizing medication errors in pediatric patients. US Pharm. 2018, 44, 20–23. [Google Scholar]
- Kaushal, R.; Bates, D.W.; Landrigan, C.; McKenna, K.J.; Clapp, M.D.; Federico, F.; Goldmann, D.A. Medication errors and adverse drug events in pediatric inpatients. J. Am. Med. Assoc. 2001, 285, 2114–2120. [Google Scholar] [CrossRef] [PubMed]
- Drovandi, A.; Robertson, K.; Tucker, M.; Robinson, N.; Perks, S.; Kairuz, T. A systematic review of clinical pharmacist interventions in paediatric hospital patients. Eur. J. Pediatr. 2018, 177, 1139–1148. [Google Scholar] [CrossRef] [PubMed]
- Rishoej, R.M.; Almarsdóttir, A.B.; Christesen, H.T.; Hallas, J.; Kjeldsen, L.J. Medication errors in pediatric inpatients: A study based on a national mandatory reporting system. Eur. J. Pediatr. 2017, 176, 1697–1705. [Google Scholar] [CrossRef] [PubMed]
- Truter, A.; Schellack, N.; Meyer, J.C. Identifying medication errors in the neonatal intensive care unit and paediatric wards using a medication error checklist at a tertiary academic hospital in Gauteng, South Africa. S. Afr. J. Child Health 2017, 11, 5–10. [Google Scholar] [CrossRef] [Green Version]
- Yin, H.S.; Dreyer, B.P.; Moreira, H.A.; Van Schaick, L.; Rodriguez, L.; Boettger, S.; Mendelsohn, A.L. Liquid medication dosing errors in children: Role of provider counseling strategies. Acad. Pediatr. 2014, 14, 262–270. [Google Scholar] [CrossRef] [Green Version]
- World Health Organization. Medication Errors: Technical Series on Safer Primary Care; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
- Cunningham, K.J. Analysis of clinical interventions and the impact of pediatric pharmacists on medication error prevention in a teaching hospital. J. Pediatr. Pharmacol. Ther. 2012, 17, 365–373. [Google Scholar] [CrossRef] [Green Version]
- Benjamin, L.; Frush, K.; Shaw, K.; Shook, J.E.; Snow, S.K. American Academy of Paediatrics Committee on Pediatric Emergency Medicine; American College of Emergency Physicians Pediatric Emergency Medicine Committee; Emergency Nurses Association Pediatric Emergency Medicine Committee. Pediatric medication safety in the emergency department. Pediatrics 2018, 141, e20174066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- National Coordinating Council for Medication Error Reporting and Prevention. About Medication Errors. Available online: https://www.nccmerp.org/about-medication-errors (accessed on 18 June 2020).
- Benavides, S.; Huynh, D.; Morgan, J.; Briars, L. Approach to the pediatric prescription in a community pharmacy. J. Pediatr. Pharmacol. Ther. 2011, 16, 298–307. [Google Scholar] [CrossRef]
- Hawcutt, D.B.; Cooney, L.; Oni, L.; Pirmohamed, M. Precision dosing in children. Expert Rev. Precis. Med. Drug Dev. 2016, 1, 69–78. [Google Scholar] [CrossRef]
- Gokhul, A.; Jeena, P.; Gray, A. Iatrogenic medication errors in a paediatric intensive care unit in Durban, South Africa. S. Afr. Med. J. 2016, 106, 1222–1229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abu Farha, R.; Abu Hammour, K.; Al-Jamei, S.; Alqudah, R.; Zawiah, M. The prevalence and clinical seriousness of medication discrepancies identified upon hospital admission of pediatric patients. BMC Health Serv. Res. 2018, 18, 1–7. [Google Scholar] [CrossRef]
- Institute for Healthcare Improvement. The Five Rights of Medication Administration. Available online: http://www.ihi.org/resources/Pages/ImprovementStories/FiveRightsofMedicationAdministration.aspx (accessed on 18 June 2020).
- Elliot, M.; Liu, Y. The nine rights of medication administration: An overview. Br. J. Community Nurs. 2010, 19, 300–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thabet, Y.; Klingmann, V.; Breitkreutz, J. Drug formulations: Standards and novel strategies for drug administration in pediatrics. J. Clin. Pharmacol. 2018, 58, S26–S35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Curley, M.; Moloney-Harmon, P. Critical Care of Infants and Children, 2nd ed.; W.B. Saunders Co: Philadelphia, PA, USA, 2001. [Google Scholar]
- White, R.; Bradman, V. Handbook of Drug Administration via Enteral Feeding Tubes, 3rd ed.; Pharmaceutical Press: London, UK, 2015. [Google Scholar]
- Gaunt, M. Look-Alike, Sound-Alike Drug Names. Pharm Times. 2010. Available online: https://www.pharmacytimes.com/publications/issue/2010/December2010/MedicationSafety-1210 (accessed on 18 June 2020).
- Doyle, G.R.; McCutcheon, J.A. Clinical Procedures for Safer Patient Care; BCcampus: Victoria, BC, Canada, 2015; Available online: https://opentextbc.ca/clinicalskills/ (accessed on 18 June 2020).
- World Health Organization. Antibiotic Dosing for Children: Draft Expert Recommendations for the 2017 Essential Medicines List for Children (EMLc) Purpose and Scope of Recommendations. Available online: https://www.who.int/selection_medicines/committees/expert/21/applications/s6_ab_paed_dosing_rev.pdf (accessed on 18 June 2020).
- Hardin, A.P.; Hackell, J.M.; Committee on Practice and Ambulatory Medicine. Age limit of pediatrics. Pediatrics 2017, 140, e20172151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- World Health Organization. Preterm Birth. Available online: https://www.who.int/news-room/fact-sheets/detail/preterm-birth (accessed on 16 June 2020).
- MedlinePlus. Neonate. Available online: https://medlineplus.gov/ency/article/002271.htm (accessed on 15 June 2020).
- Yazicioǧlu, M. Approach to drug allergies in the childhood. Turk Pediatr Ars 2014, 49, 99–103. [Google Scholar] [CrossRef]
- Aspen. Co-Trimoxazole 16 mg/80 mg per mL Infusion. Available online: https://www.medicines.org.uk/emc/product/4669/smpc (accessed on 21 June 2020).
- Nunn, T. Age-Appropriate Formulations–Paediatric needs Requirement for Dosage Forms. Available online: https://www.ema.europa.eu/en/documents/presentation/presentation-age-appropriate-formulations-paediatric-needs_en.pdf (accessed on 25 June 2020).
- Pfizer Limited. Meronem IV 500 mg Powder for Solution for Injection or Infusion. Available online: https://www.medicines.org.uk/emc/product/6731 (accessed on 22 June 2020).
- Aurobindo Pharma-Milpharm Ltd. Cefalexin 500 mg Capsules. Available online: https://www.medicines.org.uk/emc/product/554/smpc (accessed on 23 June 2020).
- Yin, S.H.; Parker, R.M.; Sanders, L.M.; Dreyer, B.P.; Mendelsohn, A.L.; Bailey, S.; Patel, D.A.; Jimenez, J.J.; Kim, K.A.; Jacobson, K.; et al. Liquid medication errors and dosing tools: A randomized controlled experiment. Pediatrics 2016, 138, e20160357. [Google Scholar] [CrossRef] [Green Version]
- Orubu, E.S.F.; Tuleu, C. Medicines for children: Flexible solid oral formulations. Bull. World Health Organ. 2017, 95, 238–240. [Google Scholar] [CrossRef]
- GlaxoSmithKline. Amoxil. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050760s11,050761s11,050754s12,050542s25lbl.pdf (accessed on 25 June 2020).
- GlaxoSmithKline. Augmentin. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050575s037550597s044050725s025050726s019lbl.pdf%0Ahttps://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=17129 (accessed on 26 June 2020).
- Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2019. Available online: http://aidsinfo.nih.gov/con-tentfiles/lvguidelines/pediatricguidelines.pdf (accessed on 26 June 2020).
- World Health Organization. Antibiotic Resistance: Synthesis of Recommendations by Expert Policy Groups, Alliance for the Prudent Use of Antibiotics. 2001. Available online: https://apps.who.int/iris/handle/10665/66895 (accessed on 25 June 2020).
- British Society for Antimicrobial Chemotherapy. Antimicrobial Stewardship from Principles to Practice. 2018. Available online: http://www.bsac.org.uk/antimicrobialstewardshipebook/BSAC-AntimicrobialStewardship-FromPrinciplestoPractice-eBook.pdf (accessed on 26 June 2020).
- American Society of Health-Systems Pharmacists. ASHP–PPAG Guidelines for Providing Pediatric Pharmacy Services in Hospitals and Health Systems. Am. J. Health Pharm. 2018, 75, 1151–1165. [Google Scholar] [CrossRef]
- Cipolle, R.; Strand, L.; Morley, P. Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services, 3rd ed.; McGraw-Hill Education: New York, NY, USA, 2012. [Google Scholar]
- Hermanspann, T.; van der Linden, E.; Schoberer, M.; Fitzner, C.; Orlikowsky, T.; Marx, G.; Eisert, A. Evaluation to improve the quality of medication preparation and administration in pediatric and adult intensive care units. Drug Healthc. Patient Saf. 2019, 11, 11–18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zahreddine, L.; Hallit, S.; Shakaroun, S.; Al-Hajje, A.; Awada, S.; Lahoud, N. Knowledge of pharmacists and parents towards antibiotic use in pediatrics: A cross-sectional study in lebanon. Pharm. Pract. 2018, 16, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- National Hand Hygiene Initiative. 5 Moments for Hand Hygiene. Available online: https://www.safetyandquality.gov.au/publications-and-resources/resource-library/5-moments-hand-hygiene-poster-paediatrics (accessed on 25 June 2020).
Term | Definition |
---|---|
Adolescent | Patient between the ages of 12 to 21 years |
Child | Paediatric patient between the ages of 2 to 12 years |
Infant | Paediatric patient between the ages of 0 to 24 months |
Neonate | Paediatric patient from birth to 28 days of age |
Preterm | Neonate born before 37 weeks of gestation |
Term | Neonate born at 39 weeks of gestation |
Toddler | Paediatric patient between the ages of 1 and 2 years |
Medicine | Product Concentration | Calculating the Dose |
---|---|---|
amoxicillin (PO) | 125 mg/5 mL | 125 mg/5 mL |
250 mg/5 mL | 250 mg/5 mL | |
ferrous gluconate (PO) | 350 mg/5 mL (elemental iron 8 mg/1 mL) | 8 mg/1 mL 40 mg/5 mL |
ferrous lactate (PO) | 15 mg/0.6 mL | 15 mg/0.6 mL |
ibuprofen (PO) | 100 mg/5 mL | 100 mg/5 mL |
paracetamol (PO) | 120 mg/5 mL | 120 mg/5 mL |
vitamin D (PO) | 200 units/1 drop | 200 units/1 drop |
amoxicillin/clavulanic acid (PO) | 125 mg/31.25 mg/5 mL | 125 mg/5 mL |
250 mg/62.5 mg/5 mL | 250 mg/5 mL | |
amoxicillin/clavulanic acid (IV) | 500 mg/100 mg | 500 mg |
1000 mg/200 mg | 1000 mg | |
piperacillin/tazobactam (IV) | 4000 mg/500 mg | 4000 mg |
trimethoprim/sulfamethoxazole (PO) | 40 mg/200 mg/5 mL | 40 mg/5 mL |
80 mg/400 mg/tablet | 80 mg/1 tablet | |
trimethoprim/sulfamethoxazole (IV) | 80 mg/400 mg/5 mL | 80 mg/5 mL |
Class | Medicine Name |
---|---|
Antibiotics | amikacin, amoxicillin, cefazolin, cefepime, cefotaxime, cefuroxime, ceftazidime, gentamicin, meropenem, piperacillin/tazobactam, sulfamethoxazole, tobramycin, vancomycin |
Anti-fungal | amphotericin B, fluconazole |
Anti-hypertensives | enalapril, milrinone, verapamil |
ART | emtricitabine, tenofovir disoproxil fumarate, lamivudine, zidovudine |
Anti-TB | ethambutol |
Class | Medicine Name |
---|---|
Anti-epileptics | carbamazepine, phenytoin, sodium valproate |
Anti-TB | isoniazid, pyrazinamide, rifampicin |
ART | efavirenz, nevirapine |
Other | cyclosporine, paracetamol |
MRP | Example | Identifying MRP |
---|---|---|
Unnecessary medicine | Patient is receiving unnecessary therapy with paracetamol. Explanation: Patient experiences no pain; thus, not indicated. | Review indication Ensure non-duplication |
Additional therapy required | Patient requires additional therapy for the prevention of TB. Explanation: Paediatric patient with family member with TB. | Review indication/current diagnosis |
Dosage too high | Ibuprofen dosage prescribed is too high to manage pain. Explanation: Ibuprofen is prescribed at a higher dosage than recommended (5 mg/kg/dose to 10 mg/kg/dose, every 6 h to 8 h). | Review dosage prescribed |
Alternative therapy | Patient requires alternative therapy for treating infection. Explanation: Patient requires alternative antibiotic. | Review indication/prescribedmedicine. |
Adverse drug reaction | Patient requires slower dose escalation of lamotrigine. Explanation: Patient experienced severe skin rash with increase in lamotrigine dose. | Evaluate patient outcome. Determine if adverse effect is due to patient’s medicine. |
Non-adherence | Patient requires a liquid formulation of sodium valproate to prevent seizures. Explanation: Patient is unable to swallow. | Evaluate patient outcome. Determine if outcomes are achieved or not. Determine challenges. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Keuler, N.; Bouwer, A.; Coetzee, R. Pharmacists’ Approach to Optimise Safe Medication Use in Paediatric Patients. Pharmacy 2021, 9, 180. https://doi.org/10.3390/pharmacy9040180
Keuler N, Bouwer A, Coetzee R. Pharmacists’ Approach to Optimise Safe Medication Use in Paediatric Patients. Pharmacy. 2021; 9(4):180. https://doi.org/10.3390/pharmacy9040180
Chicago/Turabian StyleKeuler, Nicole, Annatjie Bouwer, and Renier Coetzee. 2021. "Pharmacists’ Approach to Optimise Safe Medication Use in Paediatric Patients" Pharmacy 9, no. 4: 180. https://doi.org/10.3390/pharmacy9040180
APA StyleKeuler, N., Bouwer, A., & Coetzee, R. (2021). Pharmacists’ Approach to Optimise Safe Medication Use in Paediatric Patients. Pharmacy, 9(4), 180. https://doi.org/10.3390/pharmacy9040180